Design to come?

WP_Post Object
(
    [ID] => 2401
    [post_author] => 3
    [post_date] => 2024-10-31 16:16:12
    [post_date_gmt] => 2024-10-31 21:16:12
    [post_content] => 
    [post_title] => Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-announce-the-first-patient-dosed-in-the-randomized-presurgical-triple-negative-breast-cancer-phase-2-clinical-trial
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2024-11-20 16:17:19
    [post_modified_gmt] => 2024-11-20 21:17:19
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=2401
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)